Avastin and Lucentis, both made by the pharmaceutical company Genentech, have been found equally effective in the treatment of age . Lucentis was approved for this eye condition, while Avastin, a drug is also used off-label for age-related macular degeneration.The clinical study reported that 24 percent of patients treated with Avastin were hospitalized, compared with 19 percent of patients treated with Lucentis.
Lucentis is derived from a protein similar to Avastin – stops the growth of blood vessels in AMD.
In most cases it is enough peripheral vision to the patient to engage in some activities of daily living.
Researchers added that Lucentis trial may have an advantage because it does not need to be used as often as Avastin for some patients.
Over 250,000 patients are treated each year for AMD, and a significant number of them receive Avastin. Given the absence of efficacy data for Avastin to treat AMD, the IEN has an obligation to patients and physicians to conduct this study. age-related macular degeneration, age related macular degeneration is the leading cause of blindness and partial blindness in people aged 50 + in the United States.
Inflammatory bowel disease includes Crohn’s disease and ulcerative colitis. Its exact cause is unknown.
Individuals with AMD gradually lose their central vision, making it much more difficult to see things in front of them. The macula, also known as the macula lutea is a yellow oval spot near the center of the retina of the eye. AMD, which is caused by damage to the retina, usually affects older people.
Funded by the National Eye Institute , part of the National Institutes of Health, the comparison of AMD Treatments Trials was published in the latest issue of the New England Journal of Medicine .